Divestiture • Agriculture

SK Capital Partners Acquires Extractas Bioscience

On March 11, 2016, private equity firm SK Capital Partners acquired agriculture company Extractas Bioscience from Johnson & Johnson

Acquisition Context
  • This is SK Capital Partners’ 1st transaction in the Agriculture sector.
  • This is SK Capital Partners’ 1st transaction in Australia.

Explore All 72 Divestiture Agriculture Deals - Search the Database Free


M&A Deal Summary

Date March 11, 2016
Target Extractas Bioscience
Sector Agriculture
Buyer(s) SK Capital Partners
Sellers(s) Johnson & Johnson
Deal Type Divestiture

Target Company

Extractas Bioscience

Westbury, Australia
Extractas Bioscience is a provider in agricultural R&D and the extraction and purification of high-value plant-derived products, with a particular focus on alkaloid raw materials used in the production of active pharmaceutical ingredients. Extractas Bioscience was founded in 1975 and is based in Westbury, Australia.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.


Deal Context for Buyer #
Overall 11 of 45
Sector: Agriculture 1 of 1
Type: Divestiture 6 of 17
Country: Australia 1 of 1
Year: 2016 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-14 IBA Molecular Imaging

Dulles, Vermont, United States

IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-21 Seqens

Ecully, France

Seqens is a global diversified chemicals Group that produces and distributes essential chemicals that are used in everyday products. Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies. Seqens was founded in 2003 and is based in Ecully, France.

Buy -

Seller Profile 1

SELLER

Johnson & Johnson

New Brunswick, New Jersey, United States

Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 88.8B USD (2024)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.


Deal Context for Seller #
Overall 11 of 18
Sector: Agriculture 1 of 1
Type: Divestiture 10 of 16
Country: Australia 1 of 1
Year: 2016 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-10 Verb Surgical

Santa Clara, California, United States

Verb Surgical, Inc. is a provider of comprehensive surgical solutions platform with robotic capabilities and medical device technology for operating room professionals. Verb Surgical is based in Santa Clara, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-26 NeoStrata Co.

Princeton, New Jersey, United States

NeoStrata Co., Inc. is a developer and marketer of a comprehensive range of clinically-proven, dermatologist developed skin care brands including NeoStrata, Exuviance, CoverBlend, and Psorent.

Buy -

Explore Related M&A Activity